Moleculin Biotech (NASDAQ:MBRX) Rating Lowered to “Strong Sell” at Wall Street Zen

Moleculin Biotech (NASDAQ:MBRX) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday.

Several other research analysts have also commented on MBRX. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Moleculin Biotech in a research note on Tuesday, March 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Moleculin Biotech has a consensus rating of “Hold” and a consensus target price of $22.00.

Moleculin Biotech Price Performance

Shares of MBRX stock opened at $2.11 on Friday. The firm has a market cap of $11.27 million, a PE ratio of -0.06 and a beta of 1.74. The company has a 50-day moving average of $2.33 and a two-hundred day moving average of $4.67. Moleculin Biotech has a 1-year low of $1.79 and a 1-year high of $25.00.

Moleculin Biotech (NASDAQ:MBRX) last announced its earnings results on Thursday, May 14th. The company reported ($3.54) earnings per share for the quarter, missing the consensus estimate of ($2.33) by ($1.21). Sell-side analysts anticipate that Moleculin Biotech will post -4.89 EPS for the current fiscal year.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent SEC filing. Institutional investors and hedge funds own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.